335 related articles for article (PubMed ID: 15242253)
1. CC-5013 (Celgene).
Mitsiades CS; Mitsiades N
Curr Opin Investig Drugs; 2004 Jun; 5(6):635-47. PubMed ID: 15242253
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide as a novel therapeutic agent: new uses for an old product.
Teo SK; Stirling DI; Zeldis JB
Drug Discov Today; 2005 Jan; 10(2):107-14. PubMed ID: 15718159
[TBL] [Abstract][Full Text] [Related]
3. BMS-247550 Bristol-Myers Squibb/GBF.
Lin N; Brakora K; Seiden M
Curr Opin Investig Drugs; 2003 Jun; 4(6):746-56. PubMed ID: 12901236
[TBL] [Abstract][Full Text] [Related]
4. Epothilone D (Kosan/Roche).
Kolman A
Curr Opin Investig Drugs; 2004 Jun; 5(6):657-67. PubMed ID: 15242255
[TBL] [Abstract][Full Text] [Related]
5. OSI-461 (OSI).
Galmarini CM
Curr Opin Investig Drugs; 2004 Jun; 5(6):648-56. PubMed ID: 15242254
[TBL] [Abstract][Full Text] [Related]
6. BAY-43-9006 Bayer/Onyx.
Lee JT; McCubrey JA
Curr Opin Investig Drugs; 2003 Jun; 4(6):757-63. PubMed ID: 12901237
[TBL] [Abstract][Full Text] [Related]
7. The potential of immunomodulatory drugs in the treatment of solid tumors.
Dalgleish A; Galustian C
Future Oncol; 2010 Sep; 6(9):1479-84. PubMed ID: 20919830
[TBL] [Abstract][Full Text] [Related]
8. AE-941 (AEterna).
Dredge K
Curr Opin Investig Drugs; 2004 Jun; 5(6):668-77. PubMed ID: 15242256
[TBL] [Abstract][Full Text] [Related]
9. MS-209 Schering.
Robert J
Curr Opin Investig Drugs; 2004 Dec; 5(12):1340-7. PubMed ID: 15648956
[TBL] [Abstract][Full Text] [Related]
10. ZD-6126 AstraZeneca.
Soltau J; Drevs J
IDrugs; 2004 Apr; 7(4):380-7. PubMed ID: 15057644
[TBL] [Abstract][Full Text] [Related]
11. Diflomotecan. Ipsen.
Osheroff N
IDrugs; 2004 Mar; 7(3):257-63. PubMed ID: 15011101
[No Abstract] [Full Text] [Related]
12. TLK-286.
Verschraegen CF; Smith HO; Lee FC; Cathcart C; Norenberg JP
IDrugs; 2004 Aug; 7(8):771-81. PubMed ID: 15334311
[TBL] [Abstract][Full Text] [Related]
13. BMS-310705 Bristol-Myers Squibb/GBF.
Kolman A
Curr Opin Investig Drugs; 2004 Dec; 5(12):1292-7. PubMed ID: 15648951
[TBL] [Abstract][Full Text] [Related]
14. Learning from exceptional drug responders.
Mullard A
Nat Rev Drug Discov; 2014 Jun; 13(6):401-2. PubMed ID: 24875081
[No Abstract] [Full Text] [Related]
15. CYC-202 Cyclacel.
Guzi T
Curr Opin Investig Drugs; 2004 Dec; 5(12):1311-8. PubMed ID: 15648953
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib ditosylate GlaxoSmithKline.
Kim TE; Murren JR
IDrugs; 2003 Sep; 6(9):886-93. PubMed ID: 12964069
[TBL] [Abstract][Full Text] [Related]
17. TG-4010 Transgene.
Cohen S; Kaufman HL
Curr Opin Investig Drugs; 2004 Dec; 5(12):1319-28. PubMed ID: 15648954
[TBL] [Abstract][Full Text] [Related]
18. [Thalidomide--new prospective therapy in oncology].
Pałgan K; Pałgan I
Wiad Lek; 2003; 56(9-10):455-9. PubMed ID: 15049211
[TBL] [Abstract][Full Text] [Related]
19. New drugs target hypoxia response in tumors.
Garber K
J Natl Cancer Inst; 2005 Aug; 97(15):1112-4. PubMed ID: 16077066
[No Abstract] [Full Text] [Related]
20. The role of the National Cancer Institute in drug development.
Doroshow J
Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
[No Abstract] [Full Text] [Related]
[Next] [New Search]
